Avitide, Inc. is dedicated to the discovery and development of custom affinity purification solutions for the biopharmaceutical industry. Its technology is designed to discover and develop affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.
Avitide enables an alternative to conventional purification resin scouting and process development by providing its customers with a novel affinity capture resin. Beyond merely simplifying unit operations, the selective capture of isoforms enables the prospect of improved product definition, quality and potency. The Avitide platform reduces process development timelines, product and program risks, and cost of goods by providing turnkey, cost-effective, and highly selective affinity purification solutions. Avitide also offers access to unparalleled bioprocess intellectual property advantages compared to conventional purification technologies as a novel approach to achieve high-resolution product definition in competitive biopharmaceutical markets such as biosimilars and bio-betters.
Avitide enables an alternative to conventional purification resin scouting and process development by providing its customers with a novel affinity capture resin. Beyond merely simplifying unit operations, the selective capture of isoforms enables the prospect of improved product definition, quality and potency. The Avitide platform reduces process development timelines, product and program risks, and cost of goods by providing turnkey, cost-effective, and highly selective affinity purification solutions. Avitide also offers access to unparalleled bioprocess intellectual property advantages compared to conventional purification technologies as a novel approach to achieve high-resolution product definition in competitive biopharmaceutical markets such as biosimilars and bio-betters.
Total raised: $7.5M
Investors 5
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | S32 | s32.com |
| - | OrbiMed | orbimed.co... |
| - | Section 32 | section32.... |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.08.2015 | - | $7.5M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.06.2017 | Term Sheet — Thursday, June 22 | CORPORATE INNOVATION TOUR This is the first of three stories in a series I’m calling “Corporate Innovation Tour.” Paid Content How can you protect what you can't see? From ExtraHop Most Fortune 500 incumbents follow a pattern: Stage 1: Dism... |
| 22.06.2017 | Avitide Raises Series E Financing | Avitide, Inc., a Lebanon, N.H.-based company that specializes in the discovery, and manufacture of exclusive biopharmaceutical affinity purification solutions, closed a Series E financing. The amount of the deal was not disclosed. The round... |
| 12.09.2016 | Avitide Secures Series D Financing from Mithril | LEBANON, N.H.--(BUSINESS WIRE)--Avitide, Inc., the leader in the discovery, manufacture, and supply of novel affinity purification solutions for the biopharmaceutical industry, closed its Series D financing. Mithril Capital Management, LLC ... |
| 12.09.2016 | Avitide Secures Series D Financing from Mithril | LEBANON, N.H.--(BUSINESS WIRE)--Avitide, Inc., the leader in the discovery, manufacture, and supply of novel affinity purification solutions for the biopharmaceutical industry, closed its Series D financing. Mithril Capital Management, LLC ... |
| 06.08.2015 | Avitide Closes Series C Financing | Avitide, Inc., a Lebanon, NH-based biotech company dedicated to the discovery and development of on-demand affinity purification solutions for the biopharmaceutical industry, closed its Series C financing. The round, whose amount remained u... |
| 06.08.2015 | Avitide nets $7.5M for its next-gen biologics manufacturing process | The technology was spun out from Dartmouth College in 2013, and is chaired by storied biotech businessman Tillman Gerngross of Adimab. The company uses affinity purification to develop what it says is a highly precise biologics manufacturin... |
| 15.03.2013 | Avitide Closes Series A Financing | Avitide, Inc., a Lebanon, New Hampshire-based biotech company dedicated to the discovery and development of custom affinity purification solutions for the biopharmaceutical industry, closed their Series A financing. The amount of the fundin... |
| - | Avitide nets $7.5M for its next-gen biologics manufacturing process | New Hampshire biotech Avitide is building out a lithe platform that could turn biologics manufacturing on its head. Its simplified protein engineering and purification technology could help makers of both biologics and biosimilars develop h... |